News
DHR
245.81
-1.84%
-4.60
Danaher First Quarter 2024 Earnings: Beats Expectations
Danaher's revenue exceeded analyst estimates by 3.1%. The company's shares are up 4.6% from a week ago. Revenue is forecast to grow 6.4% in the next 3 years. Danaher reported its first quarter 2024 results on April 25th.
Simply Wall St · 6h ago
Value Vs. Growth? Danaher Says Why Not Both?
Danaher Corporation is one of the world's biggest healthcare/biotech/life sciences suppliers. The company has shown resilience and strength in its core businesses despite post-pandemic growth challenges. Danaher's shares are up 3.4%, beating the S&P 500, after its quarterly earnings report. While the company's valuation is high, Danaher benefits from secular growth trends.
Seeking Alpha · 10h ago
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
NASDAQ · 21h ago
Danaher Is Maintained at Buy by Citigroup
Dow Jones · 23h ago
Danaher Price Target Raised to $290.00/Share From $280.00 by Citigroup
Dow Jones · 23h ago
Citigroup Maintains Buy on Danaher, Raises Price Target to $290
Benzinga · 23h ago
Danaher Is Maintained at Buy by TD Cowen
Dow Jones · 23h ago
Danaher Is Maintained at Neutral by B of A Securities
Dow Jones · 23h ago
B of A Securities Maintains Neutral on Danaher, Raises Price Target to $270
Benzinga · 23h ago
Danaher Price Target Raised to $270.00/Share From $260.00 by Barclays
Dow Jones · 1d ago
Danaher Is Maintained at Equal-Weight by Barclays
Dow Jones · 1d ago
Barclays Maintains Equal-Weight on Danaher, Raises Price Target to $270
Benzinga · 1d ago
DHR Factor-Based Stock Analysis
NASDAQ · 1d ago
Tesla To $180? Here Are 10 Top Analyst Forecasts For Wednesday
Wedbush boosted the price target for Amazon.com, Inc. (NASDAQ:AMZN) from $220 to $225 on Tuesday. Spotify Technology S.A. Increased its price target from $325 to $375. Keybanc cut Pinterest, Inc.'s price target to $40.
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX), Tactile Systems Technology (TCMD) and Danaher (DHR)
TipRanks · 1d ago
Danaher Price Target Raised to $271.00/Share From $259.00 by Baird
Dow Jones · 1d ago
Danaher Is Maintained at Outperform by Baird
Dow Jones · 1d ago
Baird Maintains Outperform on Danaher, Raises Price Target to $271
Benzinga · 1d ago
RBC Capital Sticks to Its Buy Rating for Danaher (DHR)
TipRanks · 1d ago
DANAHER CORP <DHR.N>: BARCLAYS RAISES TARGET PRICE TO $270 FROM $260
Reuters · 1d ago
More
Webull provides a variety of real-time DHR stock news. You can receive the latest news about Danaher Corporation through multiple platforms. This information may help you make smarter investment decisions.
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.